These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33862461)

  • 21. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salicornia Extract Ameliorates Salt-Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a High-Fat Diet.
    Kim JH; Suk S; Jang WJ; Lee CH; Kim JE; Park JK; Kweon MH; Kim JH; Lee KW
    J Food Sci; 2017 Jul; 82(7):1765-1774. PubMed ID: 28608557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
    Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
    Han T; Fan Y; Gao J; Fatima M; Zhang Y; Ding Y; Bai L; Wang C
    Adipocyte; 2021 Dec; 10(1):446-455. PubMed ID: 34550043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro.
    Wei D; Liao L; Wang H; Zhang W; Wang T; Xu Z
    Life Sci; 2020 Apr; 247():117414. PubMed ID: 32035928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
    Lim S; Eckel RH; Koh KK
    Atherosclerosis; 2018 May; 272():33-40. PubMed ID: 29547706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice.
    Ji W; Zhao M; Wang M; Yan W; Liu Y; Ren S; Lu J; Wang B; Chen L
    PLoS One; 2017; 12(6):e0179960. PubMed ID: 28665967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcumin analog CUR5-8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity.
    Lee ES; Kwon MH; Kim HM; Woo HB; Ahn CM; Chung CH
    Metabolism; 2020 Feb; 103():154015. PubMed ID: 31758951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
    Umino H; Hasegawa K; Minakuchi H; Muraoka H; Kawaguchi T; Kanda T; Tokuyama H; Wakino S; Itoh H
    Sci Rep; 2018 May; 8(1):6791. PubMed ID: 29717156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
    Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
    Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression.
    Kawarasaki S; Sawazaki H; Iijima H; Takahashi H; Nomura W; Inoue K; Kawada T; Goto T
    Eur J Pharmacol; 2023 May; 947():175682. PubMed ID: 36965744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
    Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
    Bhagat HA; Compton SA; Musso DL; Laudeman CP; Jackson KMP; Yi NY; Nierobisz LS; Forsberg L; Brenman JE; Sexton JZ
    PLoS One; 2018; 13(10):e0204605. PubMed ID: 30359371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.
    Inoue M; Hayashi A; Taguchi T; Arai R; Sasaki S; Takano K; Inoue Y; Shichiri M
    J Diabetes Investig; 2019 Jul; 10(4):1004-1011. PubMed ID: 30461221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
    Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
    Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice.
    Nakano S; Katsuno K; Isaji M; Nagasawa T; Buehrer B; Walker S; Wilkison WO; Cheatham B
    J Clin Exp Hepatol; 2015 Sep; 5(3):190-8. PubMed ID: 26628836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.